---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-070173"
form_type: "8-K"
ticker: "LIMN"
cik: "0001971387"
company_name: "Liminatus Pharma, Inc."
filed_at: "2026-06-03T21:14:06+00:00"
generated_at: "2026-06-03T21:18:03.582116+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Liminatus Pharma raises $1.86M via warrant exercise inducement, issues new warrants for 20.7M shares

## Summary
- Gross proceeds of ~$1.86M from exercise of 10.344M existing warrants at reduced exercise price of $0.18 per share.
- Issued new unregistered warrants to purchase up to 20.688M common shares at $0.18, exercisable only after stockholder approval.
- New warrants expire five years from stockholder approval date; resale registration to be filed within 20 days.
- Maxim Group LLC acted as financial advisor, receiving 8% cash fee on gross proceeds.
- Net proceeds from the exercise will be used for working capital and general corporate purposes.

## SEC filing metadata
- accession: 0001104659-26-070173
- form_type: 8-K
- ticker: LIMN
- cik: 0001971387
- company_name: Liminatus Pharma, Inc.
- filed_at: 2026-06-03T21:14:06+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971387/000110465926070173/0001104659-26-070173-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971387/000110465926070173/tm2616851d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-070173
- JSON: https://secwatch.observer/filing/0001104659-26-070173.json
- Plain text: https://secwatch.observer/filing/0001104659-26-070173.txt

## Key facts
- Material Agreements
  Liminatus Pharma, Inc. entered into Inducement Letter Agreement with a holder of its existing common stock warrants valued at $1,861,920.00 (effective 2026-06-03).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: a holder of its existing common stock warrants
  - Value: $1,861,920.00
  - Effective: 2026-06-03
  source text: On June 3, 2026, Liminatus Pharma, Inc. (the “Company”) entered into a warrant exercise inducement offer letter (the “Inducement Letter Agreement”) with a holder (the “Holder”) of its existing common stock warrants
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971387/000110465926070173/0001104659-26-070173-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.